Back
Results - Announcements
Fermenta Biotech Ltd consolidated sales up 0.20% on year in Q2FY2026
11-Aug-2026, 03:49
Fermenta Biotech Ltd share price softened by 1.97% to Rs 548.5 after the company's net profit tanked by 48.76% to Rs 9.53 crore, while revenue from operations slightly gained 0.20% to Rs 121.82 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, rising 4.63%. It has marginally improved by 0.56% over last one week and advanced by 13.27% in last one month while the market capitalization of Fermenta Biotech Ltd has inched up 0.32% and 93.10% in the same period respectively. Profit before tax (PBT) of Fermenta Biotech Ltd stood at Rs 14.69 crore in Q2 FY26, plunging by 47.70% year-on-year, and nosediving by 43.95% quarter-on-quarter. EBITDA came in at Rs 14 crore, crashing by 29.65% YoY and slipping 8.37% sequentially. Total expenses saw a slight increase of 2.13% to Rs 108.96 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 38.75 crore, posting a minor increase of 4.33% YoY, while employee benefits expense was at Rs 23.01 crore, expanding by 7.88% YoY. For the TTM ended FY26, revenue from operations improved 11.92% to Rs 525.43 crore, while net profit eased 8.05% to Rs 70.25 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 9446% to Rs 77.45 crore, and PBT registered a growth of 15.20% to Rs 95.86 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 92.83 crore in FY26, as against Rs 40.9 crore in FY25. Fermenta Biotech Ltd rallied 58.48% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.
Fermenta Biotech Ltd share price softened by 1.97% to Rs 548.5 after the company's net profit tanked by 48.76% to Rs 9.53 crore, while revenue from operations slightly gained 0.20% to Rs 121.82 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, rising 4.63%. It has marginally improved by 0.56% over last one week and advanced by 13.27% in last one month while the market capitalization of Fermenta Biotech Ltd has inched up 0.32% and 93.10% in the same period respectively. Profit before tax (PBT) of Fermenta Biotech Ltd stood at Rs 14.69 crore in Q2 FY26, plunging by 47.70% year-on-year, and nosediving by 43.95% quarter-on-quarter. EBITDA came in at Rs 14 crore, crashing by 29.65% YoY and slipping 8.37% sequentially. Total expenses saw a slight increase of 2.13% to Rs 108.96 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 38.75 crore, posting a minor increase of 4.33% YoY, while employee benefits expense was at Rs 23.01 crore, expanding by 7.88% YoY. For the TTM ended FY26, revenue from operations improved 11.92% to Rs 525.43 crore, while net profit eased 8.05% to Rs 70.25 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 9446% to Rs 77.45 crore, and PBT registered a growth of 15.20% to Rs 95.86 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 92.83 crore in FY26, as against Rs 40.9 crore in FY25. Fermenta Biotech Ltd rallied 58.48% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.